Summit Therapeutics
Generated by Meeveem AI
"Developing ivonescimab and bispecific antibody therapies for cancer"
About Summit Therapeutics
Summit Therapeutics is a biopharmaceutical oncology company developing ivonescimab, an investigational bispecific antibody combining PD-1 blockade with inhibition of VEGF. Its HARMONi clinical programme includes Phase III studies in non-small cell lung cancer and colorectal cancer. Ivonescimab remains investigational in Summit’s territories, including the United States and Europe.
Founded in 2003, Summit is headquartered in Miami, FL, with additional offices in Palo Alto, Princeton, Oxford and Dublin. It reported 265 employees at the end of 2025, with approximately 71% working in research and development. Its teams bring together scientists, clinical development specialists, regulatory experts and business administrators to develop cancer therapies.
Learning across the organisation
Summit University leads ongoing employee education, beginning with orientation on the company, its partnership and the medicine’s mechanism of action. The company also has an employee engagement team that organises events covering wellbeing, recognition and community activities.
265
Team Members
2003
Founded
Biotechnology
Sector
Hybrid
Work Environment